1,3-benzodioxol-5-yl-methyl 2-oxopyridine-1-carboxylate | 1439368-03-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 1,3-benzodioxol-5-yl-methyl 2-oxopyridine-1-carboxylate
• 英文别名: 1,3-benzodioxol-5-ylmethyl 2-oxopyridine-1-carboxylate；1,3-Benzodioxol-5-ylmethyl-2-oxopyridine-1-carboxylate
• CAS: 1439368-03-2
• 化学式: C₁₄H₁₁NO₅
• 分子量: 273.245
• InChiKey: UWNGGLRJNRBBKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1,3-benzodioxol-5-yl-methyl 2-oxopyridine-1-carboxylate 、 [(S)-2-oxoazetidin-3-yl]ammonium acetate 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以49%的产率得到1,3-benzodioxol-5-ylmethyl N-[(3S)-2-oxoazetidin-3-yl]carbamate
  参考文献：
  名称：

  [EN] CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS
  [FR] DÉRIVÉS DE CARBAMATE D'INHIBITEURS D'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA) À BASE DE LACTAME

  摘要：

  公开号：

  WO2014144836A3
• 作为产物：
  描述：

  胡椒醇 、 碳酸二(2-吡啶)酯 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 1,3-benzodioxol-5-ylmethyl pyridin-2-yl carbonate 、 1,3-benzodioxol-5-yl-methyl 2-oxopyridine-1-carboxylate
  参考文献：
  名称：

  强大的α-氨基-β-内酰胺氨基甲酸酯作为NAAA抑制剂。合成与结构-活性关系（SAR）研究

  摘要：

  4-环己基丁基-N -[（S）-2-氧杂氮杂环丁-3-基]氨基甲酸酯（3b）是一种有效的，选择性的和系统性的细胞内NAAA活性抑制剂，可在动物模型中产生深远的抗炎作用。在当前的工作中，我们描述了对3-氨基氮杂环丁烷-2-one衍生物的结构-活性关系（SAR）研究，该研究导致了3b的鉴定，并扩展了这些研究以阐明获得有效的结构和立体化学特征。 NAAA抑制。关于2-氧代-3-氮杂环丁烷基环的β-位取代的影响以及氨基甲酸酯侧链的大小和形状的影响的研究导致了3ak的发现。，一种人类NAAA的新型抑制剂，相对于3b而言，它具有改善的理化和类药物特性。这种有利的特性以及3b氨基甲酸酯链的结构多样性，使该化合物成为研究NAAA抑制剂作为治疗疼痛和炎症的潜力的有前途的新工具。

  DOI：

  10.1016/j.ejmech.2016.01.046

文献信息

• [EN] DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)<br/>[FR] BÊTA-LACTONES DISUBSTITUÉS EN TANT QU'INHIBITEURS DE L'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA)
  申请人：UNIV CALIFORNIA

  公开号：WO2013078430A1

  公开（公告）日：2013-05-30

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，这两种物质是NAAA的底物，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的疾病的方法。
• Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)
  申请人：The Regents of the University of California

  公开号：US09353075B2

  公开（公告）日：2016-05-31

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰基乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的紊乱的方法。
• Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA)
  申请人：The Regents of the University of California

  公开号：US20130281490A1

  公开（公告）日：2013-10-24

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了一种抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和制药组合物。抑制NAAA被认为是一种维持在低浓度下的PEA和OEA的水平的方法，这两种物质是NAAA的底物。本发明还提供了治疗炎症性疾病、疼痛和其他与PEA和OEA浓度降低相关的疾病的方法。
• DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)
  申请人：Fondazione Istituto Italiano Di Tecnologia

  公开号：US20160235707A1

  公开（公告）日：2016-08-18

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-乙酰基乙醇胺酸酰化酶（NAAA）的化合物和制药组合物。抑制NAAA被认为是一种维持在PEA和OEA两种NAAA底物的水平在浓度降低的情况下的方法。本发明还提供了用于治疗炎症性疾病和疼痛以及其他与PEA和OEA水平下降相关的疾病的方法。
• CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS
  申请人：The Regents of the University of California

  公开号：US20160068482A1

  公开（公告）日：2016-03-10

  Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

  本文描述了一些化合物和药物组成物，它们可以抑制N-酰基乙醇胺酸酰化酶（NAAA）。本文还描述了合成这些化合物的方法，以及将它们制成药物组成物的方法。同时，本文还描述了抑制NAAA以维持棕榈酰乙醇胺（PEA）和其他N-酰基乙醇胺（NAE）的水平的方法，这些物质是NAAA的底物，并且在NAE浓度降低的情况下有用。此外，本文还描述了治疗和缓解疼痛、炎症、炎症性疾病和其他疾病的方法，这些疾病中脂肪酸乙醇胺的调节在临床或治疗上是相关的，或者NAE的浓度降低与该疾病有关。